Kirsty (Insulin Aspart)

Insulin Aspart mimics natural insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular pathways that move glucose‑transport proteins to the cell surface, allowing glucose to enter cells for energy use and storage, while also suppressing liver glucose production.

The dose of Kirsty is individualized. A qualified healthcare professional determines the amount, timing and frequency based on the patient’s blood‑glucose profile, carbohydrate intake, body weight, renal function and other medications. Patients should follow the prescriber’s written instructions.

Data on Insulin Aspart use in pregnancy and lactation are limited. Because uncontrolled diabetes poses greater risk to mother and fetus, clinicians may continue therapy if the benefits outweigh potential risks. Pregnant or nursing patients should discuss use with their obstetrician or endocrinologist.

To order Kirsty, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any required import documentation.

Kirsty (Insulin Aspart) has a similar onset (≈15 minutes) and peak (≈1 hour) to other rapid‑acting analogues such as insulin lispro and insulin glulisine. Its pharmacokinetic profile offers flexible dosing around meals, and clinical studies show comparable efficacy and safety. Choice among products often depends on formulary status, patient preference and provider experience.

Kirsty must be stored refrigerated between 2 °C and 8 °C. Keep the vial or cartridge in its original packaging, protect it from light, and do not freeze or shake the solution. Once in use, the product may remain at room temperature for up to 28 days, as indicated on the label.

Kirsty is supplied as a sterile solution for injection. It can be given subcutaneously using a pen, syringe or pump, typically into the abdomen, thigh or upper arm. In hospital settings it may also be administered intravenously for rapid glucose correction. Proper injection technique and site rotation are essential.

The most serious risks associated with Kirsty are severe hypoglycemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from urticaria to anaphylaxis. Patients should be educated to recognize early signs of low blood glucose and to seek immediate medical help for any suspected hypersensitivity.

Kirsty is contraindicated in individuals with a known hypersensitivity to insulin Aspart or any excipients in the formulation. It should also be avoided in patients with severe hypoglycemia until glucose levels are corrected. Clinicians must assess each patient’s medical history before initiating therapy.